Drugs Made in America Acquisition’s (NASDAQ:DMAAU – Get Free Report) quiet period is set to expire on Monday, March 10th. Drugs Made in America Acquisition had issued 20,000,000 shares in its IPO on January 28th. The total size of the offering was $200,000,000 based on an initial share price of $10.00. During Drugs Made in America Acquisition’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Drugs Made in America Acquisition Price Performance
Shares of DMAAU opened at $10.13 on Friday. Drugs Made in America Acquisition has a 52 week low of $10.00 and a 52 week high of $10.82.
Drugs Made in America Acquisition Company Profile
Featured Articles
- Five stocks we like better than Drugs Made in America Acquisition
- 3 Warren Buffett Stocks to Buy Now
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Stocks to Buy While Others Stay on the Sidelines
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.